Fierce Biotech January 10, 2024
CEO Stephen MacMillan took the microphone at the J.P. Morgan Healthcare Conference in San Francisco to describe “the new Hologic” in three words—a medtech company made “bigger, faster and stronger” in the wake of the COVID-19 pandemic.
From 2020 through early 2023, Hologic took its windfalls in coronavirus testing revenues and funded a half-dozen deals totaling $1.4 billion in M&A, aimed at bolstering its core capabilities through tuck-in acquisitions—including, but not limited to, the takeovers of cancer diagnostic developers Biotheranostics and Diagenode, as well as the infectious disease-focused Mobidiag.
“Lots of companies around the world said they were going to come out of COVID stronger. Some have, many have, but many have not. We said we would, and we...
Today's Sponsors
Today's Sponsor